Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PORT-MAP: Osanetant in Prostate Cancer
NCT05607342Phase 1Terminated
- Sponsor
- University of Kansas Medical Center
- Start
- Jan 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of osanetant in prostate adenocarcinoma, sponsored by University of Kansas Medical Center. Primary endpoint: Testosterone levels at 28 days. Started Jan 2023; status: terminated.
02
Drugs
osanetant
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on NCT05607342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05607342.